Saphris (asenapine): A New Entry Into the Ever-Growing Antipsychotic Mix

SaphrisOn August 14, 2009, the FDA approved Saphris (asenapine) as a new second-generation antipsychotic for the treatment of both schizophrenia and bipolar disorder. It is available only as a sublingual tablet, meaning that it is not effective if swallowed, and it must be left under the tongue to dissolve for it to be absorbed into the bloodstream. The available studies haven’t shown that Saphris (asenapine) provides any unique therapeutic advantage over other second-generation antipsychotics. The main contribution is that clinicians and patients will have yet another option, as if the clinical community needs another antipsychotic that is not special in any other way, and certainly not deserving of “novel” or “designer” drug status.

The manufacturer, Schering-Plough, is promoting the drug on the premise that it’s more effective at improving the negative and cognitive symptoms of schizophrenia compared to other atypical antipsychotics, and that Saphris (asenapine) has a better safety profile.

The safety profile issue has been used over and over before. While the drug demonstrated less weight gain compared to Risperdal ( risperidone) or Zyprexa (olanzapine), it has an elevated level (18%) of extrapyramidal symptoms (EPS) – comparable to first generation antipsychotics.

Schering-Plough’s specialty sales force is handling the detailing of Saphris (asenapine) – as opposed to its primary cast of sales representatives – targeting psychiatrists to prescribe this new antipsychotic.

Joseph Wegmann, R.Ph., LCSW is a licensed clinical pharmacist and a clinical social worker with more than thirty years of experience in the field of psychopharmacology. His diverse professional background in psychopharmacology and counseling affords him a unique perspective on medication management issues. In addition to consulting with numerous psychiatric facilities, he has presented psychopharmacology seminars to thousands of clinicians in 46 states. Joe has also served as a Clinical Director of Pharmacy Services at a major metropolitan area hospital and as a Regional Director of Hospital Services for Premier Healthcare Corporation. He has served as Adjunct Professor of Psychopharmacology in the graduate School of Social Work at Southern University of New Orleans for 16 years and maintains an active psychotherapy practice specializing in the treatment of depression and anxiety. Joe is the author of Psychopharmacology: Straight Talk on Mental Health Medications, published by PESI, Inc.

Comments (2)

Trackback URL | Comments RSS Feed

  1. I read about saffron in my GP’s waiting room in a glossy magazine and went out and bought safron from an Indian food outlet. I guessed 10mg and put it under my tongue twice daily about 10 days ago. I had yellow lips and a yellow tongue andfeel really good on it. I’m also taking lithium, phenelzine and quetiapine for my bipolar 1 disorder. I will take it up with my consultant and really want to get it properly prescribed. No more yellow lips!!! I’m all for trying new things. I had to stop my risperidone because of ‘tackle trouble’ = impotence and feel hornier and more frisky altogether. Thank you. Derek Liverpool

  2. Mark MS says:

    Saphris is a new antipsychotic drug. Saffron is a yellow spice, the stamen from a flower, to be exact. They are completely different things. The fact that you felt better is great but it was only a placebo effect.

Leave a Reply




If you want a picture to show with your comment, go get a Gravatar.